In Q2 fiscal 2026 (the quarter ended June 30, 2026), Penumbra's largest product or service was Thrombectomy, with $258.98 million or 66% of revenue, up 12.5% from a year earlier. Next: Embolization and Access (34%).
By region, United States brought in 78% and Non-US brought in 22% of revenue in Q2 fiscal 2026.
By country, UNITED STATES brought in 78% and Non-US brought in 22% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Embolization and Access (+20.0%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Fiscal quarters, from company filings
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Thrombectomy | $259.0M | $253.9M | $236.4M | $230.3M | 66% |
| Embolization and Access | $131.1M | $120.8M | $118.3M | $109.2M | 34% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $305.4M | $296.4M | $275.0M | $260.8M | 78% |
| Non-US | $84.6M | $78.4M | – | $78.6M | 22% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Country | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| UNITED STATES | $305.4M | $296.4M | $275.0M | $260.8M | 78% |
| Non-US | $84.6M | $78.4M | – | $78.6M | 22% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Thrombectomy: $258.98 million, or 66% of revenue, in Q2 fiscal 2026.
By revenue in Q2 fiscal 2026: Thrombectomy (66%) and Embolization and Access (34%).
By region in Q2 fiscal 2026: United States (78%) and Non-US (22%).
Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i
Every item and period in one grid. Purple = calculated; "–" = not available.
| Item |
|---|